Chemomab Therapeutics Ltd Stock Price, News & Analysis

Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced upcoming investor conference presentations. CEO Dr. Adi Mor will deliver corporate presentations at two events:

1. H.C. Wainwright 26th Annual Global Investment Conference: A prerecorded webcast available from September 9, 2024, at 7:00 am ET for 90 days.

2. HBM Biopharma Summit 2024 in Zurich, Switzerland: A live in-person presentation scheduled for September 23, 2024, at 10:45 am CET at the Park Hyatt Zurich.

The H.C. Wainwright presentation will be accessible via webcast, while the HBM Summit presentation will not be webcast. These presentations offer investors insights into Chemomab's innovative therapeutics for high unmet need fibro-inflammatory diseases.

Chemomab Therapeutics (Nasdaq: CMMB) reported positive Phase 2 results for CM-101 in Primary Sclerosing Cholangitis (PSC), demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company completed a $10 million PIPE financing, extending its cash runway through early 2026. Key highlights include:

- CM-101 met primary and secondary endpoints in the SPRING trial
- First therapy to show broad effects on PSC's main components
- Statistically significant reduction in liver stiffness after 15 weeks
- Planning for Phase 3 PSC trial and FDA discussions
- Q2 2024 financials: $12.8 million cash position, $2.9 million R&D expenses, $0.8 million G&A expenses
- Net loss of $3.6 million or $0.01 per share

Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, has announced that it will release its second quarter 2024 financial results on August 21, 2024, at 7:00 am Eastern Time. The company will also provide a business update along with the financial report. Investors interested in discussing the financial results or business update after the earnings release can contact the company at IR@chemomab.com.

Chemomab Therapeutics (Nasdaq: CMMB) has successfully closed a $10 million private placement, extending its cash runway potentially to early 2026. The financing, which involved both existing and new investors including HBM Healthcare Investments, OrbiMed, and Sphera Biotech Master Fund LP, positions the company to achieve key clinical milestones in Q1 2025 while advancing discussions with potential partners based on positive Phase 2 results.

The private placement involved the sale of 8,097,167 ADSs and pre-funded warrants at a price of $1.235 per ADS, without warrant coverage. Oppenheimer & Co. Inc. acted as Capital Markets Advisor, with LifeSci Capital and Maxim Group also advising. The company has agreed to file a registration statement with the SEC for the resale of the issued securities.

Chemomab Therapeutics (Nasdaq: CMMB), a clinical-stage biotech company focusing on fibro-inflammatory diseases, has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification letter from Nasdaq confirming that it has met the closing bid price of $1.00 or greater for 10 consecutive business days from July 9 to July 22, 2024. This resolves the non-compliance issue initially reported on November 6, 2023, when Chemomab's American Depositary Shares (ADSs) had fallen below the $1.00 threshold for more than 30 consecutive business days. With this development, Nasdaq has closed the matter, affirming Chemomab's continued listing on the exchange.

Chemomab Therapeutics (Nasdaq: CMMB) has announced a $10 million private placement (PIPE) with participation from new and existing investors. The company is selling 4,188,867 American Depositary Shares at $1.235 per share and pre-funded warrants to purchase up to 3,908,300 ADSs. This funding is expected to extend Chemomab's cash runway through early 2026, supporting operations for about a year after two major milestones anticipated in early 2025.

The proceeds will be used to fund development programs for CM-101, their innovative therapeutic for fibro-inflammatory diseases, as well as general corporate purposes. The PIPE is set to close around July 26, 2024, subject to customary closing conditions. Oppenheimer & Co. Inc. is acting as Capital Markets Advisor for the transaction.

Chemomab Therapeutics (Nasdaq: CMMB) has reported positive topline results from its Phase 2 SPRING trial of CM-101, a first-in-class monoclonal antibody, in patients with primary sclerosing cholangitis (PSC). The trial met its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple secondary efficacy endpoints.

Key findings include:

• Statistically significant improvement in liver stiffness, a important PSC disease marker
• Reduction in total bilirubin, an important marker of cholestasis and liver health
• Improvements in pruritis, a cholestatic indicator relevant to patients
• Favorable safety profile and general tolerability over the 15-week treatment period

The company plans to advance CM-101 to a Phase 3 PSC trial in 2025, following discussions with the FDA later this year.

Chemomab Therapeutics announced new publications reinforcing the clinical potential of its CCL24-neutralizing antibody, CM-101, in treating primary sclerosing cholangitis (PSC). A study published in the International Journal of Molecular Science used machine learning to analyze proteomic profiles from PSC patient sera, confirming that high levels of CCL24 are linked to PSC severity and cirrhosis. This highlights the possibility of CM-101 as an effective therapy. A second study in Drug Safety reported that CM-101 showed good tolerability and reduced biomarkers of inflammation and fibrosis in Phase 1 trials. Topline data from the Phase 2 PSC trial is expected mid-2024.

Chemomab Therapeutics shared promising data at EASL 2024 and the Gordon Research Conference, showcasing the potential of CM-101 as a novel treatment for Primary Sclerosing Cholangitis (PSC). The studies highlighted CM-101's anti-fibrotic activity, evidenced by reduced liver fibroblast activation in ex vivo assays using patient samples. New translational data confirmed CM-101's disease-modifying effects in PSC. Proteomic profiling and machine learning developed a protein signature predicting PSC severity, reinforcing the therapeutic targeting of CCL24. These findings are pivotal as Chemomab approaches topline results from its Phase 2 PSC trial.